Skip to main content
. 2017 Feb 10;8(3):388–394. doi: 10.7150/jca.16804

Table 3.

The characteristics of patients after propensity score analyses.

Propensity score-matched patients
Variable Total Right-side colon Left-side colon Rectum P-value, chi-square
Number of patients 487 136 172 179
Age
≤50 y 230 67 85 78 0.787
51-65 y 176 46 61 69
>65 y 81 23 26 32
Gender
Male 302 78 107 117 0.348
Female 185 58 65 62
Mucinous histology
Yes 81 27 30 24 0.295
No 406 109 142 155
Stage at diagnosis
I 6 1 1 4 <0.001
II 48 13 11 24
III 163 39 47 77
IV 270 83 113 74
First line therapy
Chemotherapy 243 58 86 99 0.084
Bevacizumab + chemotherapy 244 78 86 80
Metastatic organ
1 345 100 115 130 0.662
>1 142 36 57 49
CEA
≤5 ng/ml 138 31 53 54 0.216
>5 ng/ml 346 105 117 124
unknown 3 0 2 1
LDH
≤245 U/ml 346 101 114 131 0.262
>245 U/ml 140 35 57 48
unknown 1 0 1 0
Backbone chemotherapy
Oxaliplatin-based 190 52 72 66 0.903
Irinotecan-based 257 73 87 97
5-fluorouracil only 40 11 13 16
Bevacizumab beyond first line
Yes 57 18 152 160 0.773
No 430 118 20 19
Cetuximab treated
Yes 55 13 21 21 0.655
No 432 123 151 158
Primary tumor resection
Yes 166 43 54 69 0.285
No 321 93 118 110